Ajanta Pharma Limited Stock Price Today (NSE: AJANTPHARM)
Fundamental Score
Ajanta Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Ajanta Pharma Limited share price today is ₹3508.90, down 0.04% on NSE/BSE as of 16 September 2026. Ajanta Pharma Limited (AJANTPHARM) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹43.98K (Cr). The 52-week high for AJANTPHARM share price is ₹3796.00 and the 52-week low is ₹2329.90. At a P/E ratio of 38.63x, AJANTPHARM is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 25.39% and a debt-to-equity ratio of 0.05.
Ajanta Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Ajanta Pharma Limited share price chart: 2.08% return over the past month. 52-week high ₹3796.00, 52-week low ₹2329.90.
Ajanta Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹3482.40 | ₹3530.80 | ₹3460.00 | ₹3508.90 | 1.16L (Cr) | |
| ₹3555.90 | ₹3555.90 | ₹3477.10 | ₹3510.40 | 78.12K (Cr) | |
| ₹3516.00 | ₹3560.00 | ₹3460.00 | ₹3533.40 | 45.55K (Cr) | |
| ₹3515.00 | ₹3550.00 | ₹3480.00 | ₹3520.00 | 20.45K (Cr) | |
| ₹3605.00 | ₹3609.00 | ₹3512.30 | ₹3534.40 | 41.84K (Cr) | |
| ₹3513.40 | ₹3597.00 | ₹3483.30 | ₹3579.30 | 1.13L (Cr) | |
| ₹3445.00 | ₹3539.00 | ₹3438.00 | ₹3513.60 | 72.59K (Cr) | |
| ₹3503.50 | ₹3521.10 | ₹3455.30 | ₹3464.80 | 65.35K (Cr) | |
| ₹3462.60 | ₹3536.70 | ₹3456.10 | ₹3521.10 | 42.78K (Cr) | |
| ₹3504.80 | ₹3544.00 | ₹3425.00 | ₹3481.70 | 99.44K (Cr) |
Ajanta Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹3623.00 | ₹3630.70 | ₹3425.00 | ₹3508.90 | -3.15% | |
| ₹3485.50 | ₹3796.00 | ₹3403.10 | ₹3601.90 | +3.34% | |
| ₹3422.70 | ₹3598.80 | ₹3254.80 | ₹3465.20 | +1.24% | |
| ₹2936.30 | ₹3479.00 | ₹2851.50 | ₹3422.70 | +16.57% | |
| ₹2868.40 | ₹3314.90 | ₹2850.00 | ₹2928.90 | +2.11% | |
| ₹2849.90 | ₹2934.00 | ₹2696.60 | ₹2822.70 | -0.95% | |
| ₹2830.00 | ₹3228.00 | ₹2739.10 | ₹2805.10 | -0.88% | |
| ₹2810.00 | ₹3054.00 | ₹2756.90 | ₹2993.90 | +6.54% | |
| ₹2787.60 | ₹3020.80 | ₹2654.50 | ₹2781.90 | -0.20% | |
| ₹2565.00 | ₹2824.00 | ₹2513.60 | ₹2768.90 | +7.95% | |
| ₹2483.60 | ₹2622.00 | ₹2445.80 | ₹2560.80 | +3.11% | |
| ₹2391.00 | ₹2511.00 | ₹2379.30 | ₹2465.30 | +3.11% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Ajanta Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ajanta Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AJANTPHARM across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (25.39%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (31.83%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (27.70%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (29.22%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (24.82%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (13.54% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Conservative Debt Levels (D/E: 0.05)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (86.52x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.85)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹2666.49 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (66.25%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 29.48%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
3 factors identified
High Price-to-Book Ratio (9.72x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Weak Earnings Growth (2.40% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
High Share Pledging Risk (22.53%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
Ajanta Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Ajanta Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Ajanta Pharma LimitedAjanta Pharma L...Selected✓ AJANTPHARM • 532331 | 53.5/100 | ₹3508.90₹3509 | ₹43984.06₹43984.06 | 38.63Average 38.6 Average | 25.39%Excellent 25.39% Excellent | 31.83%Excellent 31.83% Excellent | 0.05Excellent 0.0 Excellent | 10.06%Good 10.06% Good | 13.54%Good 13.54% Good | 0.81% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Ajanta Pharma Limited PE Ratio History
Historical price-to-earnings ratio for AJANTPHARM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹73.53 | ₹2768.90 | 37.7x |
| FY 2024 | ₹64.77 | ₹2932.20 | 45.3x |
| FY 2023 | ₹45.89 | ₹2083.65 | 45.4x |
| FY 2022 | ₹54.96 | ₹1211.95 | 22.1x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Ajanta Pharma Limited Dividend History
Annual cash dividends paid by AJANTPHARM — dividend yield 0.81%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹349.37 Cr |
| FY 2024 | ₹642.17 Cr |
| FY 2023 | ₹89.69 Cr |
| FY 2022 | ₹82.21 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Ajanta Pharma Limited Quarterly Performance
Latest quarterly metrics for AJANTPHARM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
24.82%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
29.22%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.54%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
10.06%
Compounded annual net profit growth over 5 years
Ajanta Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AJANTPHARM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Ajanta Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Ajanta Pharma Limited (AJANTPHARM) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Ajanta Pharma Limited
About AJANTPHARM (Ajanta Pharma Limited)
Ajanta Pharma Ltd is a dynamic pharmaceutical company committed to developing and delivering innovative healthcare solutions across a diverse range of therapeutic areas. With a foc...us on specialty pharmaceutical formulations, Ajanta Pharma blends scientific expertise with cutting-edge manufacturing processes to create high-quality medicines designed to address unmet medical needs. The company's product portfolio encompasses a broad spectrum of dosage forms, from conventional tablets and capsules to advanced injectables and inhalers, reflecting its dedication to providing versatile treatment options for patients. Ajanta Pharma's unwavering pursuit of excellence drives its commitment to research and development, enabling it to consistently introduce novel products that improve patient outcomes and enhance the quality of life. Ajanta Pharma's strategic approach to the pharmaceutical market involves a dual focus on chronic and acute therapies, catering to both long-term health management and immediate medical interventions. This comprehensive strategy allows the company to address a wide range of patient needs and contribute to overall healthcare advancement. The company's branded generic products are recognized for their reliability and affordability, making essential medications accessible to a broader population. Ajanta Pharma's dedication to quality extends beyond its product offerings, encompassing rigorous quality control measures throughout the entire manufacturing process, ensuring that every medicine meets the highest standards of safety and efficacy. Ajanta Pharma operates with a global vision, serving diverse therapeutic areas such as cardiology, dermatology, ophthalmology, and pain management. This diversified approach enables the company to navigate the complexities of the pharmaceutical landscape and adapt to evolving healthcare needs. By consistently investing in research and innovation, Ajanta Pharma strives to be at the forefront of pharmaceutical advancements, developing solutions that address critical health challenges worldwide. The company's commitment to ethical business practices and patient-centric values underpins its mission to improve health outcomes and make a positive impact on communities worldwide.
Company Details
Key Leadership
AJANTPHARM Share Price: Frequently Asked Questions
What is the current share price of Ajanta Pharma Limited?
Ajanta Pharma Limited (AJANTPHARM) trades at ₹3508.90 on NSE and BSE. Market cap ₹43.98K (Cr). Educational data only.
What is the P/E ratio of Ajanta Pharma Limited?
Ajanta Pharma Limited has a P/E of 38.63x vs industry average 34.89x.
What is the Bull Run score for Ajanta Pharma Limited?
Ajanta Pharma Limited has a Bull Run score of 53.5/100 based on 25+ financial parameters.
Does Ajanta Pharma Limited pay dividends?
Ajanta Pharma Limited has a dividend yield of 0.81%. Past dividends don't guarantee future payments.
What is the ROE of Ajanta Pharma Limited?
Ajanta Pharma Limited has ROE of 25.39%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Ajanta Pharma Limited?
Ajanta Pharma Limited has debt-to-equity of 0.05.
Is Ajanta Pharma Limited a good investment?
Bull Run gives Ajanta Pharma Limited a score of 53.5/100. This is not investment advice — consult a SEBI-registered advisor.